Keytruda cleared for NHS use in early head and neck cancer MSD's Keytruda is poised to end a 20-year drought in new advances in NHS treatment for early-stage head and neck cancer

#Keytruda #pembrolizumab #immunotherapy #headandneckcancer #PharmaNews #MSD #NICE #reimbursement #NICEfinaldraftguidance #NHSEngland #headandnecksquamouscellcarcinoma #HNSCC #LAHNSCC #PDL1biomarker #PD1inhibitor #KEYNOTE689trial #perioperativeimmunotherapy #PDL1positiveHNSCC
zurl.co/y2cQh

Incyte breaks new ground in anal cancer with EU approval Incyte claims EU approval for Zynyz as the first systemic therapy for anal cancer, as J&J gets the nod for wider use of Akeega in prostate cancer.

A regimen based on #Incyte's #PD1inhibitor Zynyz and chemotherapy has become the first systemic treatment to be approved in the #EU for advanced squamous cell carcinoma of the anal canal (#SCAC).

Emma Walmsley upholds £40B sales target in her final GSK CEO report Emma Walmsley and her GSK CEO successor, Luke Miels, are safeguarding the British pharma’s 40 billion-pound-sterling sales projection for 2031 on the back of a strong quarter. | Emma Walmsley and her ...

#GSK #EmmaWalmsley #LukeMiels #Blenrep #Arexvy #Shingrix #multiplemyeloma #PD1inhibitor #Jemperli #rectalcancer #antibodydrugconjugates #ADCs #HansohPharma #FDAapproval #longactingbiologic #depemokima #chronicrhinosinusitis #biologics #vaccines #shinglesvaccine #RSVvaccine
zurl.co/iumHW

Akeso PD-1 inhibitor cleared as Keytruda challenger advances Akeso has bagged an FDA approval for its PD-1 inhibitor penpulimab and reported new data on highly-touted PD-1/VEGF bispecific ivonescimab.

NEWS: Hong Kong's #Akeso has ended the week on a high note, with an #FDA approval for its #PD1inhibitor penpulimab and more data on PD-1/VEGF bispecific antibody ivonescimab.

pharmaphorum.com/news/akeso-p...